The ABPI Pharmacovigilance Expert Network (PEN) recognises the value of using digital media to communicate externally with customers and gather information. Despite the obvious benefits of using digital media, there are regulatory and legal considerations due to the inherent nature of this channel.
Attention to company values, legal and policy requirements are necessary for successful participation in the social media environment. These guidance notes provide suggested best practices for the monitoring and management of adverse events (AE) and product complaints (PC) from digital media use in both company sponsored and non-company sponsored digital media. They have been developed by the ABPI and shared with the Medicines and Healthcare Products Regulatory Agency (MHRA).